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Venezuelan equine encephalitis virus (VEEV) is an arbovirus that causes periodic outbreaks that impact
equine and human populations in the Americas. One of the VEEV subtypes located in Mexico and
Central America (IE) has recently been recognized as an important cause of equine disease and death,
and human exposure also appears to be widespread. Here, we describe the use of an Internal Ribosome
Entry Site (IRES) from encephalomyocarditis virus to stably attenuate VEEV, creating a vaccine
candidate independent of unstable point mutations. Mice infected with this virus produced antibodies
and were protected against lethal VEEV challenge. This IRES-based vaccine was unable to establish
productive infection in mosquito cell cultures or in intrathoracically injected Aedes taeniorhynchus,
demonstrating that it cannot be transmitted from a vaccinee. These attenuation, efﬁcacy and safety
results justify further development for humans or equids of this new VEEV vaccine candidate.
& 2012 Elsevier Inc. All rights reserved.Introduction
Venezuelan equine encephalitis virus (VEEV; family Togaviridae,
genus Alphavirus), the etiologic agent of Venezuelan equine encepha-
litis (VEE), is an arthropod-borne virus (arbovirus) of signiﬁcant
medical and veterinary importance throughout Central and South
America. VEEV causes neurologic disease in horses, and infected
people typically present with nonspeciﬁc ﬂu-like symptoms including
fever, malaise and headaches. The virus can cause encephalitis and
death, but such severe manifestations are mostly observed in
children. The epidemiology of VEE is complicated by the presence
of several antigenic subtypes. Viruses within the VEE antigenic
complex comprise antigenically and geographically distinct subtypes
(IAB, IC, ID, IE, II–VI). Historically, major epidemics have been caused
by the IAB and IC subtypes, which arise from ID enzootic progenitors
(Brault et al., 2002; Greene et al., 2005). Enzootic subtypes circulate
continuously within a rodent/mosquito cycle, serving as an ever-
present source of future epizootic events.
Although the IE subtype has been primarily regarded as
avirulent in equids (Garman et al., 1968; Walton et al., 1973),ll rights reserved.
ology, University of Texas
: þ1 409 266 6810.
(S.C. Weaver).
aylor College of Medicine,recent data suggest that these viruses cause widespread disease
in horses and humans (Adams et al., 2012; Gonzalez-Salazar et al.,
2003; Oberste et al., 1998). Outbreaks in Mexico in 1993 and 1996
were characterized by high equine mortality from VEEV IE
infections (Oberste et al., 1998). These viruses were antigenically
indistinguishable from other previous IE Mexican isolates
(Oberste et al., 1998), and phylogenetically more similar to other
enzootic IE strains than to other equine-virulent outbreak strains
(Brault et al., 2002; Oberste et al., 1999), suggesting that VEEV IE
viruses are a previously disregarded etiologic agent of VEE in
equids and a signiﬁcantly underestimated veterinary threat.
Serosurveillance of humans, dogs, cattle and equids indicate that
many infections occur within populations located along the Gulf
Coast-bordering states of Mexico (Estrada-Franco et al., 2004),
sometimes at a high prevalence rate (Adams et al., 2012).
The VEEV genome is a single-stranded, positive-sense RNA
molecule, which is polyadenylated following the 30 untranslated
region (UTR) and capped at the 50 UTR. Two open reading frames
are translated to encode the nonstructural proteins (nsP1–4) and
the structural proteins (C, E3, E2, 6k and E1). The structural genes
are translated from a subgenomic RNA transcript generated via
the subgenomic promoter (SGP) located partially within the nsP4
gene. The subgenomic transcript is found in molar excess to the
genomic RNA, thus leading to the quick and abundant generation
of structural proteins for virion assembly (Frolov et al., 1996).
Several vaccine candidates to protect against VEE have been
generated. The best characterized, TC-83, was generated by
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83 times in guinea pig heart cells to generate attenuating point
mutations. This live-attenuated, tissue culture-adapted vaccine is
currently used to vaccinate horses and has been successful in
preventing the spread of transmission during outbreaks. Because
TC-83 is reactogenic in human volunteers and does not induce
efﬁcient immune responses in all vaccine recipients (Pittman
et al., 1996), it remains an Investigational New Drug (IND) for
human use with limited availability for at risk laboratory and
military personnel (Pittman et al., 1996). Long-term humoral
immune responses are limited against other VEEV serotypes,
particularly ID, IE, II, III and IV (Burke et al., 1977; Fillis and
Calisher, 1979), which may lead to incomplete protection from
disease. The cell culture passages used to generate TC-83 resulted
in 12 point mutations (Kinney et al., 1989), of which 2 located in
E2 gene and the 50 UTR, respectively, are responsible for the
attenuated phenotype (Kinney et al., 1993). As such, reversion to a
wild type-like phenotype is possible under certain conditions.
Furthermore, TC-83 was isolated from mosquitoes in Louisiana
following its use in halting the 1969–72 epidemics in Texas
(Pedersen et al., 1972), indicating that mosquitoes are capable
of being infected by and disseminating TC-83.
Other live-attenuated vaccines were engineered to improve
upon the aforementioned drawbacks of TC-83. A targeted muta-
genesis approach was taken to create V3526, an attenuated
IAB-based VEE vaccine with a PE2 (E2 precursor protein) cleavage
mutation and an E1 (Phe253Ser) suppressor substitution (Davis
et al., 1995). V3526 was attenuated (Ludwig et al., 2001),
immunogenic and protected adult mice from virulent IAB chal-
lenge (Davis et al., 1995; Hart et al., 2000; Pratt et al., 2003), but
the virus could still infect and disseminate within intrathoraci-
cally or orally exposed mosquitoes (Turell et al., 1999). Chimeric
vaccines, encoding the nonstructural genes from the relatively
benign Sindbis virus and the structural genes of VEEV (Paessler
et al., 2006), have the safety advantage of an attenuation mechan-
ism that is independent of point mutations and that exhibits
improved phenotypic stability (Kenney et al., 2011). However,
some of these chimeric vaccines still suffer from the ﬂaw of
potential mosquito transmission.
For these reasons, we sought to develop a vaccine that (1) is
easily tolerated, (2) contains a mechanism of attenuation inde-
pendent of unstable point mutations, and (3) cannot be trans-
mitted by mosquitoes from a vaccinee. Previously, Volkova et al.
(2008) reported on the use of an Internal Ribosomal Entry Site
(IRES) from encephalomyocarditis virus (EMCV) inserted within
the TC-83 genome that fulﬁlled the above criteria. The EMCV IRES
was selected because it functions to initiate translation inefﬁ-
ciently in insect cells while retaining strong functionality in
mammalian cells (Finkelstein et al., 1999; Woolaway et al.,
2001). This feature provided the mammalian-restricted tropism
desired for an arbovirus vaccine. TC-83 containing a mutagenized
SGP and an EMCV IRES driving translation of the structural genes
(VEEV/mutSGP/IRES) provided partial protection in mice chal-
lenged with a virulent subtype IC VEEV (Volkova et al., 2008).
However, this protection was not complete, indicating a need for
improvement (Volkova et al., 2008). Here, we describe the use of
this IRES-based technology to create a more immunogenic vac-
cine candidate to protect against the IE serotype of VEEV.Fig. 1. Diagram of the wt 68U201 VEEV genome and IRES-based vaccine
candidates. The mutated portion of the subgenomic promoter is shown on the
top, with synonymous mutations shown in lowercase and stop codons highlighted
in bold at the bottom.Results
Construction of IRES-containing 68U201 genomes
Previously, an infectious cDNA clone was generated based
upon the 68U201 strain (Powers et al., 2000), a IE subtype isolatefrom a sentinel hamster in Guatemala in 1968. Virus generated
from this clone has been well characterized in mice (Brault et al.,
2002) and is also infectious in its mosquito vector (Kenney et al.,
2012). Two basic modiﬁcations were made to this clone to
generate new VEEV vaccine candidates: 68U201/IRESv1 and
68U201/IRESv2 (Fig. 1). These variants were primarily based upon
previous studies using TC-83 (Volkova et al., 2008; Guerbois,
unpublished data) and chikungunya (Plante et al., 2011) viruses.
Brieﬂy, 68U201/IRESv1 had an EMCV IRES driving the translation
of the entire structural protein region (capsid-E1). The clone was
constructed by mutagenizing the SGP with 14 synonymous
mutations including an added opal stop codon to maintain
the amino acid sequence of nsP4 but ablate the activity of the
promoter (Fig. 1). The EMCV IRES was inserted directly after
the second engineered stop codon but before the start codon of
the capsid protein. For 68U201/IRESv2, capsid protein translation
was dependent upon the IRES. The SGP was unaltered, and
remained functional, but was directly followed by the inserted
start codon and E3 gene. The capsid gene was transferred at the
end of the E1 coding sequence, fused directly behind the EMCV
IRES sequence (Fig. 1).68U201/IRES characterization in vitro
One of the attractive features of inserting IRES in lieu of the
SGP is the ability to attenuate viral replication independently of
point mutations. In vitro attenuation of the 68U201/IRESv1 and
v2 viruses was measured by plaque size and replication curves
compared to both 68U201 and/or TC-83. The sizes and morphol-
ogies of the plaques produced from these infections are shown in
Fig. 2A. 68U201/IRESv1 and v2 viruses produced much smaller
plaques than 68U201, but similar in size to TC-83 (data not
shown). This attenuation was also reﬂected in the titers achieved
following RNA electroporation; maximum titers of either 68U201/
IRESv1 or v2 were approximately 1–5106 plaque-forming units
per milliliter (pfu/ml) whereas 68U201 vRNA produced a titer of
approximately 1108 pfu/ml under identical conditions (data not
shown). Both 68U201/IRESv1 and v2 constructs had the same
speciﬁc infectivity (PFU/mg RNA electroporated into Vero cells) as
the parental 68U201 infectious clone (data not shown).
To better quantify the replication kinetics of the IRES vaccines,
Vero cells were infected at a multiplicity of infection (MOI) of
0.1 pfu/cell and media were harvested at various time points
(Fig. 2B). At all time points tested, the titers of both 68U201 and
TC-83 exceeded those of either 68U201/IRESv1 or v2. Both
68U201/IRES viruses produced similar titers at all time points
tested (Fig. 2B). At the last time point taken, the monolayers
infected with 68U201 or TC-83 were destroyed whereas both
68U201/IRESv1 and v2 had begun to show signs of widespread
CPE.
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To determine the ability of 68U201/IRES viruses to serve as
vaccines, adult female CD1 mice were vaccinated subcutaneously68U201 IRESv1 IRESv2
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Fig. 2. In vitro characteristics of vaccine candidates, their parent strain 68U201,
and vaccine strain TC-83. (A) Vero cell plaques measured 48 hpi in a 6-well plate.
(B) Replication curves were performed in triplicate replicates at an MOI of
0.1 pfu/Vero cell. The timepoint at 1 hpi was below the limit of detection (dashed
line) and arbitrarily assigned a titer of 1 pfu/ml. Error bars denote standard deviation.
Fig. 3. Safety, immunogenicity and efﬁcacy of vaccines in mice. Female CD1 mice, aged
for 7–8 days thereafter. (A) The percent of initial weight following vaccination and (B) t
Error bars indicate standard deviation.(s.c.) with 1105 pfu and monitored for signs of illness and
changes in weight. TC-83 and 68U201 were used as controls.
All mice tolerated the 68U201/IRES vaccines well; there were
no signiﬁcant ﬂuctuations in weight or signs of illness for at least
7 days after infection, except in mice vaccinated with TC-83 on
day 4 (Fig. 3A). While this difference was statistically signiﬁcant
compared to the MOCK cohort (Po0.001), other studies with TC-83
within our laboratory did not to show this weight change on day 4,
suggesting a short-term affect within the cage. The only other mice
that showed morbidity and mortality were infected with the
parental 68U201 strain (Fig. 3A). Mice began to show signs of
illness by day 2 post-infection, which corresponded with daily
weight losses and fulﬁlled the criteria for morbidity resulting in
euthanasia.
All mice vaccinated with TC-83, 68U201/IRESv1 or v2 that
were challenged with a lethal dose of 68U201 at 1, 3, or 12
months post-vaccination were protected from morbidity and
mortality (Fig. 3B). No vaccinated mice showed statistical changes
in weight over time compared to any other groups except for the
MOCK-vaccinated group. Like after initial vaccination, the only
mice that showed signs of illness lost weight, which followed in
most cases with death (Fig. 3B and Table 1). The mouse (1 of 5,
Table 1) that survived challenge at 3 months post mock-
vaccination showed signs of illness and weight loss during the
ﬁrst 7 days, but never met euthanasia criteria. It eventually began
to gain weight and survived. Vaccinated mice challenged at one-
year post-vaccination, although fully protected against disease
resulting from 68U201 infection (Table 1), showed slight weight
loss (Fig. 3B) in the absence of overt signs of illness. This may have
been due to the old age (14 months) or the mass (49.778.3 g) of
the mice at the time of challenge. Regardless, signs of illness and6–8 weeks, were vaccinated or infected s.c. with 1105 pfu of virus, and weighed
he percent of initial weight after challenge at 1, 3, or 12 months after vaccination.
Table 1
Efﬁcacy of vaccines one to twelve months after vaccination.
Vaccine 1 month after vaccination 3 months after vaccination 12 months after vaccination
Na % Survival MDDb N % Survival MDD N % Survival MDD
MOCK 10 0 7.371.1 5 20 7.371.5 3 0 6.772.9
TC-83 19 100 n/a 5 100 n/a 3 100 n/a
68U201/IRESv1 21 100 n/a 10 100 n/a 6 100 n/a
68U201/IRESv2 12 100 n/a 10 100 n/a 7 100 n/a
a N¼number of mice in challenged cohort.
b MDD¼ mean day of death7standard deviation, after challenge with 68U201 VEEV.
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Fig. 4. Viremia following vaccination. Sera taken on day 1 post-vaccination were
titrated for the presence of virus. The limit of detection is shown as a dashed line
with a value of 67 pfu/ml. The combined data from three separate experiments
are shown.
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Fig. 6. Survival of 6-day-old mice injected intracranially with vaccines. Six-day-
old CD1 mice were injected i.c. with 2104 pfu of each virus or MOCK-infected
with PBS.
S.L. Rossi et al. / Virology 437 (2013) 81–8884weight loss were greatest in the unvaccinated mice, all of which
succumbed to infection by day 10.
Sera obtained on days 1 and 2 after vaccination were titrated
to determine viremia (Fig. 4). No mice vaccinated with 68U201/
IRESv1 or v2 produced detectable viremia on day 2, so all
comparisons were made from day 1 samples. 68U201 produced
a detectable viremia in all mice tested, with an average of
1106 pfu/ml serum. TC-83 also produced a detectable viremia
in all mice tested, but with a much lower average titer. 68U201/
IRESv1- and v2-vaccinated mice showed reductions in viremia
titer compared to both TC-83 and 68U201. Most striking was the
viremia proﬁle exhibited by 68U201/IRESv1-infected mice; fewer
than half had a detectable viremia, the average of which was
barely above the limit of detection.
The antibody proﬁles in vaccinated mice were also assessed.
Sera were harvested 3, 6, 11 and 52 weeks post-vaccination to
determine neutralizing antibodies levels by plaque reduction
neutralization test (PRNT, Fig. 5). Seroconversion was determined
by a PRNT80 titer of 1/20 or greater. By week 3, all 68U201/IRESv2
mice (17/17) and most 68U201/IRESv1 (12/16) mice had anti-
bodies that neutralized 68U201 in vitro. At week 11, all 68U201/
IRESv1 (17/17) and v2 (16/16)-vaccinated mice seroconverted.
There was no statistical difference noted between titers on weeks 3
and 11 for either 68U201/IRESv1 or v2 (one-way ANOVA). Sera
tested one year after vaccination showed the presence of 68U201-
neutralizing antibodies in most animals tested. Titers from TC-83-
vaccinated mice tested against heterologous strain 68U201 were
low, likely due to poor cross-neutralization between IAB and IE
viruses. When these sera were tested against TC-83, all mice had
high neutralizing antibody titers at all time points tested (Fig. 5).
Sera from MOCK-vaccinated mice failed to show neutralization.
68U201/IRES attenuation in 6-day-old mice
Since the 68U201/IRES vaccines were well tolerated in adult
mice, we sought to assess their attenuation in a sensitive andstrict in vivo model: intracranial (i.c.) infection of 6-day-old mice.
All mice inoculated with PBS survived and experienced normal
growth during the 2-week observation period. The highest
achievable i.c. dose, 2104 pfu/mouse, was used for all groups.
Ultimately, all viruses killed the mice, but at different times
(Fig. 6). 68U201-infected mice (N¼9) died by day 2. 68U201/
IRESv2 (N¼12) killed mice between 2 and 5 days post-infection
with a mean day of death (MDD) of 4.3 days. 68U201/IRESv1
(N¼13), on the other hand, had a MDD of 6.4 days and a
signiﬁcantly longer average survival than 68U201/IRESv2
(Po0.005, Logrank test).
Data obtained from a separate virulence study were also used
to compare the 68U201/IRES vaccines to TC-83 virulence. Six-day-
old CD1 pups injected i.c. with 2.3104 pfu of TC-83 began dying
by day 3 post-infection, with all pups succumbing to infection by
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Fig. 7. Infection of mosquito cells by vaccine strains. Vaccine stains and controls were passaged 5 times on C6/36 cells with a starting MOI of 0.1 Vero pfu/cell. (A) 48 hpi,
supernatants were analyzed by RT-PCR with primers amplifying in the nsP4 region of the genome to detect the presence of viral RNA. (B) Titers obtained from each passage
are shown. Error bars show standard deviation from duplicate samples.
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able to 68U201/IRESv2 infection in mice (Fig. 6), suggesting that
68U201/IRESv1 and v2 vaccines are similar if not less neuroviru-
lent in young mice than the current TC-83 vaccine.
68U201/IRES virus infections in mosquito cells
An attractive feature of the EMVC IRES-based arbovirus vac-
cines is their inability to replicate in mosquito cells (Finkelstein
et al., 1999; Woolaway et al., 2001). To conﬁrm this phenotype for
68U201/IRES viruses, 68U201/IRESv1 and v2 were blindly pas-
saged 5 times on C6/36 cells. 68U201 was used as a control.
Infectious virus was observed in 68U201/IRES viruses-infected
cultures only on the ﬁrst passage, likely residual inoculum virus,
which was also reﬂected in the low amount of viral RNA detected
by reverse transcriptase polymerase chain reaction (RT-PCR,
Fig. 7). At all 5 passages, 68U201 infectious virus and viral RNA
were observed at high quantities (Fig. 7A and B). These results are
consistent with blind passage of other IRES-containing alphavirus
vaccines (Pandya et al., 2012; Plante et al., 2011; Volkova et al.,
2008), reﬂecting the inability of IRES to drive translation of viral
structural proteins in insect cells.
68U201/IRES viruses in mosquitoes
Although these 68U201/IRES viruses could not replicate within
mosquito cells in culture, we also conﬁrmed their inability to
infect mosquitoes in vivo. Aedes taeniorhynchus, an epidemic
vector for VEEV, were inoculated intrathoracically (i.t.), the most
permissive route, with approximately 1103 pfu/mosquito of
68U201, 68U201/IRESv1 or 68U201/IRESv2. Cytopathic studies
performed on the clariﬁed media from homogenized whole
mosquitoes taken on day 10-post inoculation revealed infectious
virus only in the 68U201-injected mosquitoes (24/24). No homo-
genates from mosquitoes infected with 68U201/IRESv1 or v2
showed signs of CPE (0/24).Discussion
The IE VEEV subtype is genetically and geographically distinct
from others. This subtype is endemic to Central America and
Mexico, with recent outbreaks in 1993 and 1996 (Gonzalez-
Salazar et al., 2003). Historically, IE subtypes were considered
avirulent in horses, but recent ﬁndings revealed that viruses
isolated during epizootics can cause equine encephalitis
(Gonzalez-Salazar et al., 2003; Oberste et al., 1998), and human
exposure in Mexico appears to be widespread (Adams et al.,
2012). We sought to create a vaccine, for either human or equine
use, for these IE-endemic regions that would be better matched
for the viruses found in these areas, but not by the incorporationof attenuating point mutations. Instead, we used the EMCV IRES
technology applied within the IE VEEV 68U201 genome to protect
against lethal IE infection in mice. This approach has several
important features. First, the backbone was based upon a IE strain
to offer better long-term protection against VEEV strains endemic
to Central America. Second, the method of attenuation was based
upon the ablation of the subgenomic promoter’s function and the
dependence of some or all of the viral structural proteins’
translation on the EMCV IRES. We hypothesized this attenuation
is based on restricting the amount of subgenomic transcript
produced during infection, which in turn dramatically limits the
quantity of structural proteins and virions. This method, inde-
pendent of attenuating point mutations, provides phenotype
stability during virus propagation. Also, if the IRES element is
lost due to a deletion or recombination event, the resulting virus
will not be viable because the structural proteins cannot be
translated. Lastly, the IRES chosen has unique vertebrate-
restrictive translational properties, thereby dramatically reducing
the virus’ likelihood of mosquito transmission in nature.
The proof-of-concept studies on the IRES technology were ﬁrst
conducted with TC-83 (Volkova et al., 2008). Although TC-83 and
68U201 are both strains of VEEV, they reacted differently to the
incorporation of the IRES sequence. Unlike the 68U201/IRESv1,
TC-83/mutSGP/IRES had a 10-fold lower speciﬁc infectivity than
the parental TC-83 viral RNA (Volkova et al., 2008). Twenty-four
hours after electroporation, TC-83/mutSGP/IRES produced a mix-
ture of large and small plaques, indicating phenotypic and
potential genetic instability. When individual plaques were
sequenced, point mutations in nsP2 were observed that when
incorporated back into the genome, raised the speciﬁc infectivity
of the TC-83/mutSGP/IRES/1 to TC-83 levels. 68U201/IRESv1
produced uniformly small plaques 24–48 h after electroporation
and had a speciﬁc infectivity similar to the wt 68U201 infectious
clone, so the same selective pressure to create compensatory
mutations was not present in the IRES-bearing strain 68U201.
Using the murine model, we demonstrated that the IRES-
bearing 68U201 vaccine candidates are immunogenic and pro-
tective. Antibodies that neutralize the parental 68U201 virus
were detected within 3 weeks of 68U201/IRESv1 vaccination,
but not within all vaccinated mice. In comparison, all 68U201/
IRESv2-vaccinated mice produced detectable neutralizing anti-
bodies by week 3, suggesting that v2 may be more rapidly
immunogenic. However, by week 11, both 68U201/IRESv1 and
v2 produced neutralizing antibodies in all mice. A PRNT80 titer of
20, considered to be alphavirus-protective in vivo (Paessler and
Weaver, 2009), was achieved by most of the 68U201/IRES-
vaccinated mice at the time of challenge (1 month post-infection),
and antibody titers remained high a year post-vaccination. How-
ever, even mice that lacked a detectable PRNT80 titer (e.g. most
TC-83- and some 68U201/IRES-vaccinated mice) were still
fully protected against lethal challenge, indicating that other
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(Brooke et al., 2010; Paessler et al., 2007), are probably important.
In addition to being immunogenic, the 68U201/IRES vaccines
also showed properties associated with increased safety, both
virological and environmental, compared to TC-83. Both 68U201/
IRESv1 and v2 were just as attenuated, if not more, than TC-83
when injected i.c. into infant mice. The survival curves for TC-83
and 68U201/IRESv2 showed no statistical difference, but 68U201/
IRESv1 was attenuated compared to both as measured in mean
days’ survival. Because only the highest achievable dose was used,
it is possible that lower inoculated doses would reveal a differ-
ence in virulence between TC-83 and 68U201/IRESv2. Second, the
levels of viremia in 68U201/IRES-vaccinated mice were reduced
in titer and duration compared to both 68U201 and TC-83.
No 68U201/IRES were detected in the serum after the ﬁrst day
following vaccination. This limits the timeframe for a potential
transmission event from the vaccinee to a mosquito. Furthermore,
this possibility of transmission of the IRES-based vaccines is
remote because they are unable to infect mosquitoes. Even
following i.t. inoculation, the most permissive route of infection,
neither 68U201/IRESv1 nor v2 replicated within A. taeniorhynchus
mosquitoes.
The encouraging results from our initial studies with these
IRES-based 68U201 VEE vaccines indicate that further develop-
ment is warranted. Although lower doses of our vaccine may be
sufﬁcient to protect horses from VEEV disease (Fine et al., 2007),
increasing the titers generated by Vero cells of our vaccines would
be advantageous. Work is currently ongoing to increase these
titers by serial passage in several cell lines approved for vaccine
development. Additional studies are also needed to further test
the efﬁcacy of our IRES-based VEE vaccines, including protection
against aerosol exposure in mice and nonhuman primates (NHP).
VEEV is highly infectious by the aerosol route, which is a likely
route of accidental laboratory exposure or intentional exposure
during a terrorist attack. The latter is a particular concern as VEEV
is highly weaponizable, prompting the US government to classify
it as a Select Agent. Both murine (Steele et al., 1998) and NHP
(Reed et al., 2005) models for VEEV aerosol exposure have been
established, allowing for the efﬁcacy of the 68U201/IRES vaccines
to be measured.
The IRES-based attenuation technology described here has also
been successfully applied to other alphaviruses to create safe and
efﬁcacious vaccines (Pandya et al., 2012; Plante et al., 2011;
Volkova et al., 2008). The technology is easily transferable
between different alphaviruses because the mechanism of
attenuation is a property of changes the alphavirus gene expres-
sion, and not of a particular virus strain. It therefore should be
applicable to other known or as yet unidentiﬁed alphavirus that
may emerge in the future.Materials and methods
Cell lines and viruses
Vero (green monkey kidney) cells were maintained in Dulbecco’s
minimum essential medium (DMEM) supplemented with 5–6% fetal
bovine serum (FBS) and penicillin/streptomycin (P/S). BHK-21 (baby
hamster kidney) cells were maintained in DMEM with 10% FBS and
P/S. C6/36 (Aedes albopictus) mosquito cells were grown in BHK
media supplemented with 1% tryptose broth phosphate (TBP). All
mammalian cells were stored at 37 1C while insect cells were grown
at 29 1C. All of the viruses in this study were rescued from cells
transfected with in vitro transcribed RNA generated from infectious
clone cDNA templates. In some cases, viruses were passed once in
Vero cell culture to increase titer and create stocks for use.Vaccine clone construction
The infectious cDNA clone derived from VEEV subtype IE strain
68U201 has been described previously (Powers et al., 2000), and
served as the parental plasmid for all manipulations. 68U201/
IRESv1 was created by mutagenizing the SGP with 14 mutations
and by inserting the capsid gene-fused IRES (Fig. 1). Brieﬂy, the
SGP was mutated, the 50 UTR of the subgenomic RNA was deleted
and a unique ClaI site was added upstream of the EMCV IRES-
capsid fusion using the following primers in 3 PCR reactions. The
VEEV/mutSGP/IRES clone was used as a PCR template to amplify
the EMCV IRES sequence (Volkova et al., 2008). Primers that
annealed within nsP4 or capsid were used to obtain PCR and ﬁnal
fusion PCR products. The fusion PCR product was ligated into the
68U201 genome between the NheI and BspHI sites.
The 68U201/IRESv2 infectious cDNA clone was constructed
similarly. The capsid gene was deleted from the 68U201 infec-
tious cDNA by PCR mutagenesis such that the E3 gene contained
the ATG start codon and began directly after the SGP. Capsid, with
ﬂanking start and stop codons, was fused to the IRES sequence
and inserted within the 30UTR (Fig. 1).
All ﬁnal constructions were sequenced and found to have no
unexpected changes through the PCR-ampliﬁed regions. A list of
all primers used in generating these constructs is available upon
request.Vaccine rescue and titration
RNA was in vitro transcribed from linearized cDNA using the
T7 Ambion mMessage mMachine kit (Austin, Texas), then elec-
troporated into BHK or Vero cells. In some cases, the cDNA
template was destroyed by DNase treatment and the RNA was
precipitated by LiCl and ethanol as per the manufacturer’s proto-
col. The ﬁnal RNA concentration was determined by UV spectro-
photometry. Electroporation conditions were as follows using the
BTX electropororator (Harvard apparatus company, Holliston,
MA): BHK (2 mm cuvette, 680 V, 10 pulses at 99 ms, 100 ms
interval with unipolar polarity) and Vero (4 mm cuvette, 350 V,
1 pulse at 7 ms, 100 ms interval with unipolar polarity). Virus was
harvested from clariﬁed (287G for 5 min) supernatants col-
lected 24 and 48 h after electroporation.
All viruses were titrated on Vero cell monolayers. Brieﬂy, serial
dilutions of virus were allowed to adsorb to the monolayers for
1 h prior to overlaying with DMEM supplemented with 2% FBS
and 0.4% agarose. Approximately 2 days after infection, mono-
layers were ﬁxed with formaldehyde and subsequently stained
with 0.5% crystal violet to visualize plaques. All titers are
expressed as pfu/ml. Speciﬁc infectivity was determined by
titrating an aliquot of freshly electroporated cells onto Vero cell
monolayers, then overlaying the plates as done for titration.
Speciﬁc infectivity was measured by counting the number of
plaques produced by electroporated cells divided by the amount
of RNA used for the electroporation.Replication curves
Vero cells seeded into 6-well plates were infected in triplicate
with virus at a MOI of 0.1 pfu/cell for 1 h at 37 1C, then washed
4 times with media prior to adding 2.1 ml of DMEM containing
2% FBS and P/S. Immediately thereafter, 100 ml of culture ﬂuid
was removed for the 1 h post-infection (hpi) titration. At each
timepoint (12, 24, 36, 48 hpi), 100 ml of cell culture supernatant
were removed and replaced with fresh media. Supernatants were
titrated in 12-well plates as described above.
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All animal work was performed in accordance with UTMB
policy as approved by the UTMB Institutional Animal Care and
Use Committee. Adult female CD1 mice (Charles River, Wilming-
ton, MA), aged approximately 6–8 weeks, were injected s.c. in the
right hind leg or back with 100 ml of virus diluted in DMEM with
2% FBS, or with PBS. All inocula were titrated to conﬁrm dose.
Vaccinated and challenged mice were observed daily for signs of
illness (including rufﬂed fur, hunched posture and hind limb
paralysis) for 7–10 days. Individual weight measurements were
also recorded. During the vaccination phase of the experiment,
mice were considered moribund if they exhibited paralysis,
extreme lethargy or greater than a 20% loss in initial body weight.
However, moribund criteria during the challenge experiments did
not include the weight loss. Moribund mice that were euthanized
were recorded as dead on the following day.
Mice were bled retro-orbitally and clariﬁed serum was tested
for the presence of virus by plaque assay, or for neutralizing
antibody by plaque reduction neutralization test (PRNT, see
below). One capillary tube (volume 70 ml) of blood was com-
bined with 225 ml of PBS prior to clariﬁcation by centrifugation
for 5 min at 3380G. PBS-diluted serum was removed and stored
at 80 1C. Blood samples within cohorts were taken on days
1 and 2 to determine levels of viremia. Mice held for long-term
antibody studies were bled on weeks 3, 6, 11 and 52 post-
vaccination.
Intracranial inoculations were performed on 6-day-old off-
spring from individual litters of pregnant CD1 mice. Approxi-
mately 20 ml of virus inoculum was injected i.c. into each mouse,
and pups were monitored daily for survival.
Plaque reduction neutralization test
Sera obtained from mice 3, 6, 11 and 52 weeks post-vaccination
were tested for the presence of neutralizing antibody by PRNT.
Individual sera were heat inactivated at 56 1C for 1 h, then chilled
prior to use. Two-fold dilutions were incubated with 70 ml (approxi-
mately, 800 pfu/ml) of 68U201 or TC-83 for 1 h at 37 1C, after which
Vero cell monolayers were infected with the serum/virus mixture as
described for virus titration. Plaques were counted at each dilution to
determine the PRNT80 titers for the corresponding serum, i.e. the
serum dilution at which there was at least a 80% reduction in the
number of plaques observed with the uninfected mouse serum.
Approximately 20–30 plaques were observed in monolayers incu-
bated with uninfected murine serum.
Serial passages
Serial passages in C6/36 cells were performed in duplicate in
6-well plates without intermediate titration. The ﬁrst passage was
infected at an MOI of 0.1 pfu/cell (based upon Vero titers) for one
hour, cells were then washed 4 times with 1 ml PBS and ﬁnally
covered with 2 ml of C6/36 media and maintained at 29 1C.
Supernatants were harvested 48 h post-infection, centrifuged
5 min at 1791G and 3 aliquots of 450 ml were placed at
80 1C. Subsequent passages were performed by infecting
C6/36 cells with 400 ml of the previous passage.
One aliquot from each passage was used to perform a plaque
titration on Vero cells and to isolate viral RNA. Viral RNA
extraction was performed on 100 ml of supernatant using the
QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, CA), as per
manufacturer’s instructions, with a ﬁnal elution volume of
50 ml. Reverse-transcription polymerase chain reaction (RT-PCR)
was performed on 2.5 ml of isolated vRNA using QIAGEN OneStepkit (per manufacturer’s protocol) with primers annealing
within nsP4.
Mosquito infections
A. (Ochlerotatus) taeniorhynchus derived from a colony founded
from adult females collected near Talahassee, Florida were
i.t.-inoculated with 1 ml of undiluted 68U201/IRESv1 or 68U201/
IRESv2 stocks, as well as a titer-matched dilution of 68U201
(1106 PFU/ml). Fifty female mosquitoes were injected per virus,
plus one cohort was injected with PBS as control. After injection,
mosquitoes were incubated for 10 days at 27 1C, then placed
individually into 2 ml tubes containing 350 ml DMEM supplemen-
ted with 10% FBS, 1% P/S and Fungizone (amphotericin B) at a ﬁnal
concentration of 5 mg/ml. Whole mosquitoes were homogenized
in Qiagen Tissue Lyser II for 4 min at 26p/sec, then supernatants
were clariﬁed by centrifugation for 5 min at 1791G. Vero cells
were infected with 100 ml of clariﬁed supernatant, incubated for
1 h at 37 1C, then covered with 1 ml DMEM 2% FBS, and kept for
5 days with monitoring for signs of cytopathic effects (CPE).
Statistical analyses and graph presentation
Prism software (Version 4, GraphPad Software, La Jolla, CA)
was used for both the statistical analyses as well as the graphical
generation of data. Signiﬁcances in weight were performed using
a two-way ANOVA with a Bonferroni Post-Test. PRNT80 and
viremia statistics were performed using a one-way ANOVA with
a Tukey’s Multiple Comparisons Post-Test. Statistics on survival
curves were analyzed using the Logrank Test.Acknowledgments
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